Aldicarb

Aldicarb

SCHEMBL2887130

CNC(=O)O/N=C/C(C)(C)SC.NCCCCC(N)C(=O)O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Aldicarb. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.61
GSR P00390 1/20 0.46
TSHR P16473 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NOS2 P35228 7/20 0.38
NOS1 P29475 7/20 0.38
NOS3 P29474 6/20 0.38
CYP2C19 P33261 2/20 0.38
THPO P40225 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
BLM P54132 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DDAH1 O94760 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aldicarb SCHEMBL8778632 0.97 TDP1 (0.63) TDP1GSRTSHRALDH1A1HSD17B10
Aldicarb SCHEMBL20568578 0.86 TDP1 (0.64) TDP1GSRTSHRALDH1A1HSD17B10
Cystine SCHEMBL14645188 0.83 TDP1 (0.68) TDP1TSHRALDH1A1HSD17B10NOS2
Aldicarb SCHEMBL214691 0.83 TDP1 (0.68) TDP1TSHRALDH1A1HSD17B10NOS2
Aldicarb SCHEMBL21327721 0.80 TDP1 (0.90) TDP1TSHRALDH1A1HSD17B10
Aldicarb SCHEMBL7626286 0.78 TDP1 (1.00) TDP1TSHRALDH1A1HSD17B10
Aldicarb SCHEMBL3901576 0.77 TDP1 (0.90) TDP1TSHRALDH1A1HSD17B10
Aldicarb SCHEMBL9464143 0.77 TDP1 (0.90) TDP1TSHRALDH1A1HSD17B10
Aldicarb SCHEMBL9464151 0.77 TDP1 (0.90) TDP1TSHRALDH1A1HSD17B10
Aldicarb SCHEMBL9028720 0.77 TDP1 (0.96) TDP1TSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1946416-A Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window KENNETH S WARREN INST INC (US) 2007-04-11 CN claimed
CN-1897960-A Tissue protective cytokines for protection, restoration, and enhancement of responsive cells, tissues and organs with extended therapeutic window KENNETH S WARREN INST INC (US) 2007-01-17 CN claimed
US-7722858-B2 Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2010-05-25 US disclosed
US-7476551-B2 Diagnosing atherosclerosis risk by measuring carbamylated low density lipoprotein levels THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2009-01-13 US disclosed
WO-2007092625-A2 PREVENTION AND TREATMENT OF ATHEROSCLEROSIS BY REDUCING CARBAMYLATION OF LDL OR THE EFFECTS OF CLDL THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2007-08-16 WO disclosed
US-20060183245-A1 Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL BIOVENTURES, LLC 2006-08-17 US disclosed
US-20030045004-A1 Prevention and treatment of atherosclerosis by reducing carbamylation of LDL or the effects of carbamylated LDL VETERANS AFFAIRS, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF 2003-03-06 US disclosed